Physician profile
Ali Salem
NPI 1376983122
$4,030.53
in general payments reported to CMS, 2019-2025
27 companies · $753 in 2025
The $753 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $237 · 2021: $244 · 2022: $720 · 2023: $680 · 2024: $1,134 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,567.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,756.58 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Ucb, INC. | $365.43 | 2023-2025 | Briviact, Nayzilam |
| Amgen INC. | $258.46 | 2024-2025 | Tezspire, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $237.71 | 2019-2020 | |
| Pfizer INC. | $203.89 | 2020-2025 | |
| Genzyme Corporation | $140.48 | 2022-2024 | |
| Itamar Medical INC | $138.43 | 2025 | Watchpatone |
| Regeneron Healthcare Solutions, INC. | $117.65 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $104.06 | 2022-2024 | |
| Inspire Medical Systems, INC. | $103.22 | 2025 | Inspire |
| Boston Scientific Corporation | $101.64 | 2021 | |
| Xeris Pharmaceuticals, INC. | $56.42 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.82 | 2021-2023 | Xifaxan |
| Grifols USA, LLC | $51.30 | 2023-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $45.26 | 2025 | Uptravi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.19 | 2025 | Ofev, Jascayd |
| Sanofi-Aventis U.S. LLC | $30.93 | 2025 | |
| Resmed Corp | $29.68 | 2024-2025 | |
| Baxter Healthcare | $29.24 | 2022 | |
| Lilly USA, LLC | $27.93 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.81 | 2022 | |
| Merck Sharp & Dohme LLC | $24.17 | 2024 | Winrevair |
| United Therapeutics Corporation | $21.86 | 2025 | Tyvaso |
| Revance Therapeutics, INC. | $18.13 | 2025 | Daxxify |
| Dexcom, INC. | $16.34 | 2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $14.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Salem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.